



Small, but heading for the big time

Nanobiotix revenue for Q2 2015

Paris, France, July 15, 2015 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2015.

Income statement

<i>In €</i>	Q2 2015	H1 2015	Q2 2014	H1 2014
Revenues	46,189	93,180	48,596	93,939
Of which :				
<i>License</i>	45,160	91,191	45,847	91,190
<i>Services</i>	1,029	1,989	2,749	2,749

Activity

NANOBIOTIX's revenue during the second quarter of 2015 corresponds to the upfront payment (pro-rata share) received by the company from Taiwan-based PharmaEngine, within the framework of the licensing contract signed in August 2012 for the development and commercialization of the lead product, NBTXR3 in the Asia-Pacific region. It is distributed using the straight-line method of apportioning the revenue across the period between the date the contract was signed and the scheduled marketing launch in the region. This upfront payment totaled €810,640, generating revenue of €45,160 over the period and totaling €91,191 for the first semester in 2015. The invoicing of services totaled €1,029 for the second quarter of 2015. In total, revenue for the second quarter amounted to €46,189. Revenue for the first half of 2015 is €93,180 which is fully in line with company expectations.

During the first quarter, the Company announced major clinical achievements. In May, Nanobiotix expanded Soft Tissue Sarcoma pivotal phase II/III clinical trial with NBTXR3 across Europe. The clinical trial is running in clinical centers of excellence in four European countries so far (France, Belgium, Spain, and Hungary). Clinical authorization requests are ongoing in other European countries, in Canada and in Asia-Pacific region via its partner, PharmaEngine. Interim results are expected to be announced in mid-2016, product registration (CE mark) is anticipated towards the end of 2016.

In June, Nanobiotix reported positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3. Intermediate results showed the feasibility of the injection of NBTXR3 and a good safety profile of the product for this indication. Moreover, the good safety results allowed the enlargement of the targeted population to patients treated in combination with radiotherapy plus chemotherapy. These interim results represent one step further for use and transferability of NBTXR3 therapeutic approach in different types of tumors.

•••

Next financial press release: revenue for the first half of 2015 to be released on September 1st, 2015



About NANOBOTIX: www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of cancers including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers, Prostate Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma, locally advanced Head and Neck Cancer, Rectum cancer (PharmaEngine) and Liver cancers. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO:FP). The company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.

Contact

Nanobiotix

Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
contact@nanobiotix.com



Media relations

France - NewCap
Annie-Florence Loyer
+33 (0)6 88 20 35 59
afloyer@newcap.fr

Outside France - Instinctif Partners
Melanie Toyne Sewell / Jayne Crook
+44 (0) 207 457 2020
nanobiotix@instinctif.com

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2014 annual financial report of Nanobiotix (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.